Skip to main content
Premium Trial:

Request an Annual Quote

Sequenom Goes Public, Stock Soars 200 Percent

Premium

S

AN DIEGO--Sequenom made an initial public offering earlier this month of 6 million shares of stock at $26 per share, which yielded gross proceeds of about $157 million. The shares gained more than 200 percent and closed day one at nearly $80.

The company, which calls itself an industrial genomics firm addressing the large-scale commercial use of DNA variations for improving health, agriculture, and livestock, said its intellectual property portfolio includes 47 pending patent applications in the US. Sequenom’s MassArray system performs high-throughput analysis of SNPs. The technology is presently being tested at six academic, government, and commercial sites.

Filed under

The Scan

Boosters Chasing Variants

The New York Times reports that an FDA advisory panel is to weigh updated booster vaccines for COVID-19.

Not Yet

The World Health Organization says monkeypox is not yet a global emergency, the Washington Post reports.

More Proposed for Federal Research

Science reports that US House of Representatives panels are seeking to increase federal research funding.

PLOS Papers on Breast Cancer Metastasis, Left-Sided Cardiac Defects, SARS-CoV-2 Monitoring

In PLOS this week: link between breast cancer metastasis and CLIC4, sequencing analysis of left-sided cardiac defects, and more.